Regular aspirin use and gene expression profiles in prostate cancer patients
- PMID: 29915914
- PMCID: PMC6298857
- DOI: 10.1007/s10552-018-1049-5
Regular aspirin use and gene expression profiles in prostate cancer patients
Abstract
Purpose: Pharmacoepidemiology studies suggest prognostic benefits of aspirin in prostate cancer. We hypothesized that aspirin induces transcriptional changes in tumors or normal prostate tissue.
Methods: We analyzed the prostatic transcriptome from men diagnosed with prostate cancer during follow-up of the Physicians' Health Study 1 (PHS, n = 149), initially a randomized controlled trial of aspirin. Aspirin target genes were identified through systematic literature review and a drug target database. We compared target gene expression according to regular aspirin use at cancer diagnosis and used whole-transcriptome gene set enrichment analysis to identify gene sets associated with aspirin use. Results were validated in the Health Professionals Follow-up Study (HPFS, n = 254) and in Connectivity Map.
Results: Of 12 target genes identified from prior studies and 540 genes from the drug target database, none were associated with aspirin use. Twenty-one gene sets were enriched in tumor tissue of aspirin users, 18 of which were clustered around ribosome function and translation. These gene sets were associated with exposure to cyclooxygenase inhibitors in Connectivity Map. Their association with cancer prognosis was U-shaped in both cohorts. No gene sets were enriched in normal tissue. In HPFS, neither the target genes nor the gene sets were associated with aspirin use.
Conclusions: Regular aspirin use may affect ribosome function in prostate tumors. Other putative target genes had similar expression in tumors from aspirin users and non-users. If results are corroborated by experimental studies, a potential benefit of aspirin may be limited to a subset of prostate cancer patients.
Keywords: Aspirin; Prognosis; Prostate cancer; Ribosome; Transcriptome.
Conflict of interest statement
Figures

Similar articles
-
Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physicians' Health Study.Eur Urol. 2017 Nov;72(5):821-827. doi: 10.1016/j.eururo.2017.01.044. Epub 2017 Feb 8. Eur Urol. 2017. PMID: 28189429 Clinical Trial.
-
A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status.Cancer Epidemiol Biomarkers Prev. 2018 Oct;27(10):1231-1233. doi: 10.1158/1055-9965.EPI-18-0510. Epub 2018 Aug 14. Cancer Epidemiol Biomarkers Prev. 2018. PMID: 30108097 Free PMC article.
-
Influence of regular aspirin intake on PSA values, prostate cancer incidence and overall survival in a prospective screening trial (ERSPC Aarau).World J Urol. 2020 Oct;38(10):2485-2491. doi: 10.1007/s00345-019-03054-5. Epub 2019 Dec 21. World J Urol. 2020. PMID: 31865534
-
Aspirin use in relation to risk of prostate cancer.Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):1108-11. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12376516
-
Effect of long term aspirin use on the incidence of prostate cancer: A systematic review and meta-analysis.Crit Rev Oncol Hematol. 2018 Dec;132:66-75. doi: 10.1016/j.critrevonc.2018.09.013. Epub 2018 Sep 29. Crit Rev Oncol Hematol. 2018. PMID: 30447928
Cited by
-
Deep Transcriptome Profiling of Multiple Myeloma Using Quantitative Phenotypes.Cancer Epidemiol Biomarkers Prev. 2023 May 1;32(5):708-717. doi: 10.1158/1055-9965.EPI-22-0798. Cancer Epidemiol Biomarkers Prev. 2023. PMID: 36857768 Free PMC article.
References
-
- Grytli HH, Fagerland MW, Fossa SD, Tasken KA. Association between use of beta-blockers and prostate cancer-specific survival: a cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol. 2014;65:635–41. - PubMed
-
- Cardwell CR, Flahavan EM, Hughes CM, et al. Low-dose aspirin and survival in men with prostate cancer: a study using the UK Clinical Practice Research Datalink. Cancer Causes Control. 2014;25:33–43. - PubMed
-
- Flahavan EM, Bennett K, Sharp L, Barron TI. A cohort study investigating aspirin use and survival in men with prostate cancer. Ann Oncol. 2014;25:154–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 CA167552/CA/NCI NIH HHS/United States
- P50 CA090381/CA/NCI NIH HHS/United States
- HL34595/HL/NHLBI NIH HHS/United States
- R01 HL034595/HL/NHLBI NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- 5P50 CA090381/CA/NCI NIH HHS/United States
- R01 HL026490/HL/NHLBI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- R01 CA040360/CA/NCI NIH HHS/United States
- R01 CA097193/CA/NCI NIH HHS/United States
- P30 CA008748/CA/NCI NIH HHS/United States
- HL26490/HL/NHLBI NIH HHS/United States
- Young Investigator Award/Prostate Cancer Foundation
- CA34944/CA/NCI NIH HHS/United States
- R01 CA034944/CA/NCI NIH HHS/United States
- CA097193/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical